IMMUNOMODULATORS IN OPPORTUNISTIC INFECTIONS TREATMENT

Abstract. The immune status and the level of specific antibodies to Cytomegalovirus (121 patients) or Mycoplasma pneumoniae (129 patients) were tested in 250 patients aged 19–56 years old. This cohort was divided for three groups. Seventy eight patients with low level of CD3+CD4+ lymphocytes and nor...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: A. P. Toptygina, G. V. Bobyleva, V. A. Alioshkin
Formato: article
Lenguaje:RU
Publicado: Sankt-Peterburg : NIIÈM imeni Pastera 2014
Materias:
cmv
Acceso en línea:https://doaj.org/article/23b7251ac5fc4b1798ee639a097512a8
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
Descripción
Sumario:Abstract. The immune status and the level of specific antibodies to Cytomegalovirus (121 patients) or Mycoplasma pneumoniae (129 patients) were tested in 250 patients aged 19–56 years old. This cohort was divided for three groups. Seventy eight patients with low level of CD3+CD4+ lymphocytes and normal rates of other parameters of immune status were jointed in Group 1. The second group was presented by 85 patients with low level of CD3+CD4+ and high level of CD3+CD8+ lymphocytes. Eighty seven patients with lymphopenia were distinguished in Group 3. All patients were treated with antiviral or antibacterial and immunomodulatory drugs. Three schemes of immunomodulatory therapy including imunofanum, polyoxidonium, cycloferonum, glutoxim, immunomax in different combination were used. In three weeks after treatment in 72,4% of patients no clinical symptoms as well as normalization of immune status indices and decrease of specific antibodies titers were observed. Sixty nine patients reported improvement of subjective health status, however they had high level of specific antibodies. Immunological examination of these patients after second course of immunomodulatory therapy confirmed their convalescence. It was shown that the condition of immune status determines effect of the different immunomodulators.